Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Assets: 2010-2025

Historic Assets for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $189.4 million.

  • Anika Therapeutics' Assets fell 18.14% to $189.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.4 million, marking a year-over-year decrease of 18.14%. This contributed to the annual value of $202.7 million for FY2024, which is 25.09% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Assets is $189.4 million, which was up 0.94% from $187.7 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Assets peaked at $363.1 million during Q2 2021, and registered a low of $187.7 million during Q2 2025.
  • Over the past 3 years, Anika Therapeutics' median Assets value was $262.7 million (recorded in 2024), while the average stood at $254.1 million.
  • Per our database at Business Quant, Anika Therapeutics' Assets climbed by 0.46% in 2022 and then declined by 29.48% in 2024.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Assets stood at $347.5 million in 2021, then grew by 0.46% to $349.1 million in 2022, then decreased by 22.48% to $270.6 million in 2023, then decreased by 25.09% to $202.7 million in 2024, then decreased by 18.14% to $189.4 million in 2025.
  • Its Assets was $189.4 million in Q3 2025, compared to $187.7 million in Q2 2025 and $190.6 million in Q1 2025.